.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,439,911

« Back to Dashboard

Details for Patent: 9,439,911

Title:Topical formulations comprising a steroid
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s): Ubaidulla; Udhumansha (Namakkal, IN), Kandavilli; Sateesh (Hyderabad, IN), Vairale; Ajay Sunil (Hyderabad, IN), Wayne; Jeffrey A. (Markham, CA), Nalamothu; Vijendra (Basking Ridge, NJ), Meghal; Mistry (Ahmedabad, IN), Pakunlu; Refika Isil (Highland Park, NJ)
Assignee: Dr. Reddy's Laboratories Ltd. (Hyderabad, Telangana, IN)
Filing Date:Apr 21, 2016
Application Number:15/135,298
Claims:1. A sprayable topical pharmaceutical composition, comprising: at least one steroid; a non-polymeric emulsifying agent comprising sorbitan stearate; water; and a water-immiscible substance; wherein the composition is substantially non-occlusive to the skin.

2. The composition according to claim 1, wherein the steroid is selected from the group consisting of alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, and fluticasone propionate.

3. The composition according to claim 1, and further comprising a polymer.

4. The composition according to claim 3, wherein the polymer is selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate.

5. The composition according to claim 3, wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

6. The composition according to claim 1, wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

7. The composition according to claim 1, and further comprising a penetration enhancer.

8. The composition according to claim 7, wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

9. The composition according to claim 8, wherein the penetration enhancer is selected from the group consisting of a polyol and esters, ethers, sulfoxides, fatty acids, fatty acid esters, and any combination thereof.

10. The composition according to claim 3, wherein the steroid is selected from the group consisting of betamethasone dipropionate and betamethasone valerate; and polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

11. The composition of claim 1, wherein the composition forms droplets upon application.

12. The composition of claim 1, wherein the composition is substantially non-foaming.

13. The composition of claim 1, wherein said composition is substantially free of a propellant.

14. The composition of claim 1, wherein the composition is substantially free of propylene glycol.

15. A sprayable topical pharmaceutical composition, comprising: a betamethasone compound; a non-polymeric emulsifying agent comprising sorbitan stearate; water; and a water-immiscible substance; wherein the topical pharmaceutical composition is is substantially non-occlusive to the skin.

16. The composition according to claim 15, wherein the betamethasone compound is in amounts equivalent to about 0.025 to about 0.1 percent by weight of betamethasone base.

17. The composition according to claim 15, wherein the betamethasone compound is betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

18. The composition according to claim 15, comprising a polymer selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate.

19. The composition according to claim 15, wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

20. The composition according to claim 15, wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

21. The composition according to claim 15, and further comprising a penetration enhancer.

22. The composition of claim 21, wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

23. The composition according to claim 15, wherein the betamethasone compound is betamethasone dipropionate; and the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

24. The composition according to claim 15, wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

25. The composition of claim 15, wherein the composition forms droplets upon application.

26. The composition of claim 15, wherein the composition is substantially non-foaming.

27. The composition of claim 15, wherein said composition is substantially free of a propellant.

28. The composition of claim 15, wherein the composition is substantially free of propylene glycol.

29. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 1 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.

30. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 15 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc